权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional Proteomics by Reverse Phase Protein Array in Cancer

癌症中反相蛋白阵列的功能蛋白质组学

基本信息

批准号：
10251202
负责人：
YILING LU
金额：
$ 14.53万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-19 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10251202
关键词：
Antibody Repertoire Applications Grants Atlases Automation Award Biological Models Cancer Center Cancer Center Support Grant Cells Collaborations Communities Contractor DNA sequencing Data Data Set Disease Drug Combinations Ensure Environment Epigenetic Process Funding Generations Genomics International Journals Malignant Neoplasms Medicine Nature New England Paper Patients Peer Review Grants Pharmacodynamics Phase Prognostic Marker Protein Array Proteins Proteome Proteomics Publications Research Research Personnel Resources Sampling Science Services Signal Pathway Signal Transduction Systems Biology Technology The Cancer Genome Atlas Time University of Texas M D Anderson Cancer Center Visualization Work anticancer research cBioPortal career development clinical application cost effective design epigenomics improved interest metabolomics nano-string neoplastic cell predictive marker professor programs protein function response single cell analysis targeted cancer therapy tumor

项目摘要

PROJECT SUMMARY Dr. Yiling Lu is a Research Non-Tenure-Track-Professor at University of Texas MD Anderson Cancer Center (MDACC) where she has served as a Core Manager of the CCSG Core of Functional Proteomics by Reverse Phase protein Array (RPPA). The Core is located in the Department of Systems Biology chaired by Dr. Gordon B Mills who acting as the Primary Unit Director in this award application. The RPPA Core provides MDACC investigators, their collaborators and the cancer research community with a powerful high throughput, quantitative, cost-effective technology for functional proteomics studies. The Core has analyzed more than 125,742 samples from 547 cancer researches across from the world over the last 8 years and supported for over 265 publications including high profile journals and more then 10 million dollars of peer-reviewed grant funding from the NCI and other agencies. The most significant evidence for the utility and robustness of the RPPA Core is that its inclusion in the Cancer Genome Atlas (TCGA) analysis for each disease type and its participation in over 25 of “pancan” “markers” papers in New England Journal of Medicine, Nature, Cell and Science and their clones. In addition to the generation of high quality RPPA data, one of the key aspects of the Core is the provision of functional proteomics data to the community. This is facilitated through the RPPA data being integrated into the cBioportal and being made available for downloading, analysis and visualization through The Cancer Proteome Atlas (TCPA portal). The RPPA contributions to progress in cancer research impact this scientific field around the world. Cancer targeted therapy is designed to capitalize on the vulnerabilities of tumor cells arising from the rewiring of functional networks as a consequence of the genomic and epigenetic changes in tumor or their effects on the tumor environment, impacting cellular protein functions. Thus, direct assessment of the targeted effects, both predicted and unexpected, on the key proteins in signaling networks is required. As clarified in this application, the facility will continue to provide RPPA services to MDACC investigators and the worldwide research community. 1) The facility will continue to expand the validated antibody repertoire to cover varies signaling pathways. 2) The facility will continue to improve the quality and accuracy of RPPA data sets. 3) The facility will continue to work with a contractor to build a RPPA pipeline automation program to decrease turnaround time. 4) The facility will develop the RPPA technology to maximize its applications for clinical usage. 5) The facility will develop single cell analysis through Nanostring technology and add it to functional proteomics service to meet the interests from investigators. To ensure the utility of the RPPA resource, Dr. Lu has multiple active collaborations at MDACC, as well as, nationally and internationally for her scientific activities and career development.

项目概要陆一岭博士是德克萨斯大学MD安德森癌症中心的非终身教授她曾担任 CCSG 功能核心的核心经理通过反相蛋白阵列 (RPPA) 进行蛋白质组学。核心位于系统部生物学系由 Gordon B Mills 博士担任主席，他在本次奖项申请中担任主要部门主任。 RPPA 核心为 MDACC 研究人员、他们的合作者和癌症研究界提供服务拥有强大的高通量、定量、经济高效的功能蛋白质组学技术研究。 The Core 分析了来自 547 项癌症研究的超过 125,742 个样本过去 8 年为全球超过 265 种出版物提供支持，其中包括知名期刊以及来自 NCI 和其他机构的超过 1000 万美元的同行评审拨款资金。这 RPPA 核心的实用性和稳健性最重要的证据是它包含在每种疾病类型及其参与超过 25 种疾病的癌症基因组图谱 (TCGA) 分析新英格兰医学杂志、自然、细胞和科学杂志上的“pancan”“标记”论文及其克隆。除了生成高质量的 RPPA 数据外，Core 的关键方面之一是向社区提供功能蛋白质组学数据。这是通过 RPPA 数据实现的被集成到 cBioportal 中并可供下载、分析和通过癌症蛋白质组图谱（TCPA 门户）进行可视化。 RPPA 对进展的贡献癌症研究影响着世界各地的这一科学领域。癌症靶向治疗旨在利用功能网络重新布线所产生的肿瘤细胞的脆弱性作为肿瘤基因组和表观遗传变化的结果或其对肿瘤的影响环境，影响细胞蛋白质功能。因此，直接评估目标效果，既预测和意外的信号网络中的关键蛋白质是必需的。正如本文中所阐明的申请后，该设施将继续向 MDACC 调查员和全球研究界。 1) 该设施将继续扩大经过验证的抗体库覆盖不同的信号通路。 2）设施将不断提高质量和准确性 RPPA 数据集。 3) 该设施将继续与承包商合作建设 RPPA 管道自动化程序以减少周转时间。 4) 该工厂将开发 RPPA 技术最大限度地发挥其临床应用价值。 5) 该设施将通过以下方式开发单细胞分析纳米串技术并将其添加到功能蛋白质组学服务中以满足来自调查人员。为了确保RPPA资源的实用性，卢博士在以下领域进行了多次积极的合作： MDACC 以及国内和国际上对她的科学活动和职业发展的认可。

项目成果

期刊论文数量（56）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.

DOI：
发表时间：
2022
期刊：
American journal of cancer research
影响因子：
5.3
作者：
Shengjian Huang;Yang Liu;Zhihong Chen;Michael Wang;V. Jiang
通讯作者：
Shengjian Huang;Yang Liu;Zhihong Chen;Michael Wang;V. Jiang

Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response.

DOI：
10.1126/sciadv.aba5714
发表时间：
2020-10
期刊：
Science advances
影响因子：
13.6
作者：
Vinik Y;Ortega FG;Mills GB;Lu Y;Jurkowicz M;Halperin S;Aharoni M;Gutman M;Lev S
通讯作者：
Lev S

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.

DOI：
10.1038/s41467-018-04179-8
发表时间：
2018-05-03
期刊：
Nature communications
影响因子：
16.6
作者：
Oh SC;Sohn BH;Cheong JH;Kim SB;Lee JE;Park KC;Lee SH;Park JL;Park YY;Lee HS;Jang HJ;Park ES;Kim SC;Heo J;Chu IS;Jang YJ;Mok YJ;Jung W;Kim BH;Kim A;Cho JY;Lim JY;Hayashi Y;Song S;Elimova E;Estralla JS;Lee JH;Bhutani MS;Lu Y;Liu W;Lee J;Kang WK;Kim S;Noh SH;Mills GB;Kim SY;Ajani JA;Lee JS
通讯作者：
Lee JS

The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy.